These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 17022861

  • 21. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C.
    Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642
    [Abstract] [Full Text] [Related]

  • 22. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J, Agarwal A, Huang F, Gitlin M, Gandra SR, Cangialose CB.
    J Manag Care Pharm; 2009 Oct; 15(9):741-50. PubMed ID: 19954265
    [Abstract] [Full Text] [Related]

  • 23. [Evaluation of efficacy of darbepoetin alfa administered once monthly as treatment of anemia in predialysis patients with chronic kidney disease].
    Martínez PM, García de Vinuesa S, Ortega Díaz M, Goicoechea M, Gómez Campderá F, Luño J.
    Nefrologia; 2005 Oct; 25(6):663-7. PubMed ID: 16514907
    [Abstract] [Full Text] [Related]

  • 24. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 25. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M, Thimons DG, Winston JL, Langholff W, McGowan T.
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [Abstract] [Full Text] [Related]

  • 26. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis.
    Allon M, Kleinman K, Walczyk M, Kaupke C, Messer-Mann L, Olson K, Heatherington AC, Maroni BJ.
    Clin Pharmacol Ther; 2002 Nov; 72(5):546-55. PubMed ID: 12426518
    [Abstract] [Full Text] [Related]

  • 27. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
    Joy MS, Candiani C, Vaillancourt BA, Chin H, Hogan SL, Falk RJ.
    Pharmacotherapy; 2007 May; 27(5):734-44. PubMed ID: 17461709
    [Abstract] [Full Text] [Related]

  • 28. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
    Vanrenterghem Y, Bárány P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ, European/Australian NESP 970200 Study Group.
    Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
    [Abstract] [Full Text] [Related]

  • 29. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
    Bajo MA, Pérez Fontán M, Remón C, Sánchez-Tomero JA, Lladós F, Selgas R.
    Nefrologia; 2009 Dec; 29(2):136-42. PubMed ID: 19396319
    [Abstract] [Full Text] [Related]

  • 30. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, Hörl WH, Mattin C, Praml C, Wilkie M.
    Clin Nephrol; 2007 Mar; 67(3):140-8. PubMed ID: 17390738
    [Abstract] [Full Text] [Related]

  • 31. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J.
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M, Wühl E, Reigner SCM, Morgan Z, Schaefer F.
    Clin J Am Soc Nephrol; 2018 Jan 06; 13(1):81-90. PubMed ID: 29097481
    [Abstract] [Full Text] [Related]

  • 33. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
    Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S.
    Am J Nephrol; 2004 Jan 06; 24(4):453-60. PubMed ID: 15331889
    [Abstract] [Full Text] [Related]

  • 34. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun 06; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 35. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May 06; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 36. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA, Harpe SH, Brophy GM.
    Pharmacotherapy; 2007 Apr 06; 27(4):535-41. PubMed ID: 17381380
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr 06; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 38. Developing an algorithm to convert erythropoietin dosing to darbepoetin alfa.
    Capelli JP, Kushner H.
    Nephrol News Issues; 2006 Mar 06; 20(3):33, 35, 39 passim. PubMed ID: 16532992
    [Abstract] [Full Text] [Related]

  • 39. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta.
    Bock HA, Hirt-Minkowski P, Brünisholz M, Keusch G, Rey S, von Albertini B, Swiss EFIXNES trial investigators.
    Nephrol Dial Transplant; 2008 Jan 06; 23(1):301-8. PubMed ID: 17890745
    [Abstract] [Full Text] [Related]

  • 40. Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.
    Molina M, Navarro MJ, de Gracia C, Alvarez G, de Alarcon R, Garcia MA.
    Ren Fail; 2008 Jan 06; 30(8):778-83. PubMed ID: 18791951
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.